The Effect of GIP, GLP-1 and GLP-2 in Individuals With Genetically Altered Receptor Function
NCT ID: NCT06194955
Last Updated: 2024-05-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
60 participants
INTERVENTIONAL
2023-01-04
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Separate and Combined Extrapancreatic Effects of GIP and GLP-1
NCT06895408
The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes
NCT00732602
GIP/GLP-1 Co-Activity in Subjects With Obesity: Lowering of Food Intake
NCT02598791
GIP/GLP-1 Co-Activity in Subjects With Overweight and Type 2 Diabetes: Lowering of Food Intake
NCT03526289
The Insulin Response to the Gut Hormone GIP After Near-normalisation of Plasma Glucose in Patients With Type 2 Diabetes
NCT04228484
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants with mutations in their GLP-2 receptor will attend three randomized experimental days, E, F and G. A mixed meal test (MMT) will be performed on day E, an infusion with GLP-2 during fasting blood glucose levels will be performed on day F, and infusion with salt water (placebo) during fasting blood glucose levels will be performed on day G.
Additionally, a DXA scan and arginine test will be performed on all study participants.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GIPR variant carriers
Inidividuals with GIPR variants: Determination of the incretin effect, and the insulinotropic actions of GIP and GLP-1 infusions during hyperglycemic clamp.
GIP(1-42)
Infusion
GLP-1
Infusion
Placebo
Saline
GIPR variant carrier controls
Healthy matched individuals: Determination of incretin effect, and the insulinotropic actions of GIP and GLP-1 infusions during hyperglycemic clamp.
GIP(1-42)
Infusion
GLP-1
Infusion
Placebo
Saline
GLP-1R variant carrier
Individuals with GLP-1R variants: Determination of incretin effect, and the insulinotropic actions of GIP and GLP-1 infusions during hyperglycemic clamp
GIP(1-42)
Infusion
GLP-1
Infusion
Placebo
Saline
GLP-1R variant carrier controls
Healthy matched individuals: Determination of incretin effect, and the insulinotropic actions of to GIP and GLP-1 infusions during hyperglycemic clamp.
GIP(1-42)
Infusion
GLP-1
Infusion
Placebo
Saline
GLP-2R variant carrier
Individuals with GLP-2R variants: Determination of bone resorption marker levels (CTX) and response to GLP-2 infusions during fasting blood glucose levels
GLP-2
Infusion
Placebo
Saline
GLP-2R variant carrier control
Healthy matched individuals: Determination of bone resorption marker levels (CTX) and response to GLP-2 infusions during fasting blood glucose levels
GLP-2
Infusion
Placebo
Saline
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GIP(1-42)
Infusion
GLP-1
Infusion
GLP-2
Infusion
Placebo
Saline
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* \>10 objects of alcohol weekly or abuse of narcotics
* Liver disease (defined as ALAT and/or ASAT ≥ 2 x normal levels)
* Decreased kidney function (creatine levels over reference interval)
* Uncontrollable increased blood pressure (\> 140/90 mmHg)
* Low blood percentage (hemoglobin \< 8.3 mmol/l)
* Special diet or planned weight change during trial period
* Other conditions that could be expected to affect the primary or secondary outcomes
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gentofte Hospital, Denmark
UNKNOWN
University of Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Center for Clinical Metabolic Research, Gentofte Hospital
Hellerup, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-21044858
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.